Balancing Innovation and Control: The European Union AI Act in an Era of Global Uncertainty

Abstract

The European Union's Artificial Intelligence Act (EU AI Act), adopted in 2024, establishes a landmark regulatory framework for artificial intelligence (AI) systems, with significant implications for health care. The Act classifies medical AI as "high-risk," imposing stringent requirements for transparency, data governance, and human oversight. While these measures aim to safeguard patient safety, they may also hinder innovation, particularly for smaller health care providers and startups. Concurrently, geopolitical instability-marked by rising military expenditures, trade tensions, and supply chain disruptions-threatens health care innovation and access. This paper examines the challenges and opportunities posed by the AI Act in health care within a volatile geopolitical landscape. It evaluates the intersection of Europe's regulatory approach with competing priorities, including technological sovereignty, ethical AI, and equitable health care, while addressing unintended consequences such as reduced innovation and supply chain vulnerabilities. The study employs a comprehensive review of the EU AI Act's provisions, geopolitical trends, and their implications for health care. It analyzes regulatory documents, stakeholder statements, and case studies to assess compliance burdens, innovation barriers, and geopolitical risks. The paper also synthesizes recommendations from multidisciplinary experts to propose actionable solutions. Key findings include: (1) the AI Act's high-risk classification for medical AI could improve patient safety but risks stifling innovation due to compliance costs (eg, €29,277 annually per AI unit) and certification burdens (€16,800-23,000 per unit); (2) geopolitical factors-such as United States-China semiconductor tariffs and EU rearmament-exacerbate supply chain vulnerabilities and divert funding from health care innovation; (3) the dominance of "superstar" firms in AI development may marginalize smaller players, further concentrating innovation in well-resourced organizations; and (4) regulatory sandboxes, AI literacy programs, and international collaboration emerge as viable strategies to balance innovation and compliance. The EU AI Act provides a critical framework for ethical AI in health care, but its success depends on mitigating regulatory burdens and geopolitical risks. Proactive measures-such as multidisciplinary task forces, resilient supply chains, and human-augmented AI systems-are essential to foster innovation while ensuring patient safety. Policymakers, clinicians, and technologists must collaborate to navigate these challenges in an era of global uncertainty.

Ähnliche Arbeiten